Periplocin has anti-tumor actions in prostate cancer through modulating the miR-3614-5p/SLC4A4 axis.

Periplocin (PPLN) can inhibit malignant tumors including prostate cancer (PC), but its impact on prostate cancer is unknown. Prostate cancer cells were treated with various doses of periplocin (PPLN), and the optimal treatment concentration of PPLN was determined using a CCK-8 assay. Bioinformatics analysis was performed to examine the link between miR-3614-5p and SLC4A4. The influences of miR-3614-5p and SLC4A4 levels on prostate cancer cells were analyzed using CCK-8, EdU, cell-scratch, Transwell, and flow cytometry analyses. A nude-mouse tumor model was created by injecting mice with PC3 cells subcutaneously. MiR-3614-5p and SLC4A4 levels in cancer cells and tumor tissues were measured using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and western blot analyses. 100 nM PPLN dramatically decreased the proliferation, migration, and invasion of prostate cancer cells and promoted apoptosis. MiR-3614-5p reduced SLC4A4 levels, and both the reduction of miR-3614-5p and increase of SLC4A4 expression greatly promoted the malignancy behavior of cells. Low miR-3614-5p expression decreased PPLN's inhibitory effect on malignant behavior, which was reversed by down-regulation of SLC4A4. PPLN reduced tumor growth in mice, increased miR-3614-5p levels, and decreased SLC4A4 levels. In conclusion, PPLN exerted anti-prostate-cancer effects by modulating the miR-3614-5p/SLC4A4 axis.